Biosyent Inc (TSE:RX)
:RX
Want to see TSE:RX full AI Analyst Report?
Top Page
Biosyent
(RX)
Select Model
Select Model
Rating:77Outperform
Price Target:
C$16.50
▲(11.49% Upside)
Action:Reiterated
Date:05/16/26
The score is driven primarily by strong financial quality (high margins, low leverage, and solid cash generation). This is partially offset by weaker near-term technical signals (below key moving averages and negative MACD), while valuation is reasonable with a moderate P/E and modest dividend yield.
Positive Factors
High profitability
Sustained high gross and operating margins indicate durable product-level economics and pricing power from in-licensed therapies. Strong margins support reinvestment into commercialization, partner payments and improve resilience to pricing pressure, bolstering long-term cash generation and ROE.
Negative Factors
Uneven revenue cadence
Revenue has been lumpy historically, reflecting reliance on timing of in-licensed product launches and renewals. This uneven top-line makes forecasting and multi-period growth assumptions less certain, potentially increasing funding timing risk for commercialization investments and partner payouts.
Read all positive and negative factors
Positive Factors
Negative Factors
High profitability
Sustained high gross and operating margins indicate durable product-level economics and pricing power from in-licensed therapies. Strong margins support reinvestment into commercialization, partner payments and improve resilience to pricing pressure, bolstering long-term cash generation and ROE.
Read all positive factors
Biosyent (RX) vs. iShares MSCI Canada ETF (EWC)
Market Cap
C$160.96M
Dividend Yield1.6%
Average Volume (3M)5.67K
Price to Earnings (P/E)17.4
Beta (1Y)0.69
Revenue Growth20.13%
EPS Growth17.08%
CountryCA
Employees60
SectorGeneral
Sector StrengthN/A
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)0.81
Shares Outstanding11,497,447
10 Day Avg. Volume6,048
30 Day Avg. Volume5,666
Financial Highlights & Ratios
PEG Ratio0.59
Price to Book (P/B)3.46
Price to Sales (P/S)3.33
P/FCF Ratio14.99
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
C$16.50Price Target Upside11.49% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)0.94
Revenue Forecast (FY)C$68.60M
Biosyent Business Overview & Revenue Model
Company Description
BioSyent Inc., a specialty pharmaceutical company, sources, acquires or in-licenses, develops, and sells pharmaceutical and other healthcare products in Canada and internationally. Its products include FeraMAX 150, an oral hematinic; FeraMAX Powde...
How the Company Makes Money
Biosyent primarily makes money by commercializing healthcare products in Canada that it obtains through licensing and distribution arrangements. Key revenue streams typically include: (1) Product sales revenue from selling prescription and other h...
Biosyent Earnings Call Summary
Earnings Call Date:Aug 21, 2025
(Q2-2025)
| % Change Since: |
Next Earnings Date:Aug 25, 2026
Earnings Call Sentiment Positive
The earnings call highlighted strong revenue and profit growth across various business segments, consistent profitability, and successful dividend and share buyback programs. However, some product lines underperformed, and trade uncertainties remain a concern. Despite these challenges, the overall performance and growth initiatives present a positive outlook.Positive Updates
Strong Revenue Growth
Total company revenue was just over $10 million, representing a 14% growth compared to the previous year, with Canadian Pharma having a record quarter.
Negative Updates
Combogesic Performance Lag
Combogesic has been underperforming and lagging behind expectations for some time.
Read all updates
Q2-2025 Updates
Positive
Negative
Strong Revenue Growth
Total company revenue was just over $10 million, representing a 14% growth compared to the previous year, with Canadian Pharma having a record quarter.
Read all positive updates
Company Guidance
During the BioSyent Inc. Q2 and First Half 2025 Results Presentation, President and CEO René C. Goehrum highlighted strong financial performance with total company revenue just over $10 million for the quarter, reflecting a 14% growth compared to the previous year. Canadian Pharma achieved a record quarter with sales of $9.3 million, a 9% year-over-year increase. The company's EBITDA reached just under $2.8 million, growing by 35%, and NIAT exceeded $2 million, up 28% from the previous year, with EBITDA and NIAT margins at 27% and 20%, respectively. On a six-month basis, sales rose by 27% to over $21 million, driven by growth across Canadian Pharmaceutical, International Pharma, and Legacy business segments. EBITDA increased by 40% to nearly $6 million, while NIAT grew by 30% to over $4.3 million, with corresponding margins of 28% and 21%. The presentation also noted an EPS of $0.18 for Q2 2025, contributing to a trailing-12 month EPS of $0.72. BioSyent continued its share buyback program, repurchasing 19,500 shares year-to-date, and declared a dividend of $0.05 for September, marking an 11% increase over the previous year's dividend. The company maintained a strong cash position with $27 million as of June 30, 2025, and reported a 23% return on equity.Biosyent Financial Statement Overview
Summary
Income Statement
88
Very Positive
Balance Sheet
93
Very Positive
Cash Flow
86
Very Positive
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 45.98M | 43.05M | 35.03M | 31.59M | 27.93M | 28.62M |
| Gross Profit | 34.08M | 32.11M | 27.86M | 25.60M | 22.86M | 22.64M |
| EBITDA | 13.11M | 12.17M | 10.43M | 9.06M | 7.43M | 8.64M |
| Net Income | 9.04M | 9.01M | 7.27M | 6.46M | 5.46M | 6.28M |
Balance Sheet | ||||||
| Total Assets | 62.49M | 49.44M | 41.36M | 41.53M | 40.49M | 37.17M |
| Cash, Cash Equivalents and Short-Term Investments | 10.90M | 28.65M | 15.94M | 26.19M | 28.70M | 28.21M |
| Total Debt | 5.25M | 841.10K | 1.04M | 1.22M | 1.40M | 1.56M |
| Total Liabilities | 17.50M | 7.97M | 6.36M | 6.77M | 7.12M | 5.61M |
| Stockholders Equity | 44.99M | 41.47M | 35.00M | 34.76M | 33.36M | 31.55M |
Cash Flow | ||||||
| Free Cash Flow | 12.69M | 9.57M | 3.99M | 4.88M | 4.43M | 4.58M |
| Operating Cash Flow | 13.01M | 9.62M | 8.66M | 5.05M | 4.95M | 4.67M |
| Investing Cash Flow | -16.88M | 3.48M | 3.29M | 883.85K | -10.79M | -4.84M |
| Financing Cash Flow | -463.94K | -3.41M | -7.83M | -5.78M | -4.37M | -2.08M |
Biosyent Technical Analysis
Negative
14.80
Price Trends
14.85
Negative
14.31
Negative
12.89
Positive
Market Momentum
-0.14
Positive
34.23
Neutral
6.75
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:RX, the sentiment is Negative. The current price of 14.8 is above the 20-day moving average (MA) of 14.58, below the 50-day MA of 14.85, and above the 200-day MA of 12.89, indicating a neutral trend. The MACD of -0.14 indicates Positive momentum. The RSI at 34.23 is Neutral, neither overbought nor oversold. The STOCH value of 6.75 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TSE:RX.
Biosyent Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
77 Outperform | C$160.96M | 17.43 | 22.05% | 1.60% | 20.13% | 17.08% | |
66 Neutral | C$126.62M | 294.90 | -0.52% | ― | -7.44% | -108.29% | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
55 Neutral | C$145.11M | -10.87 | -16.54% | ― | -2.35% | 42.42% | |
50 Neutral | C$66.92M | -10.33 | -19.76% | ― | -100.00% | 87.93% | |
48 Neutral | C$200.25M | -4.76 | -229.16% | ― | ― | 18.50% | |
38 Underperform | C$663.17K | 0.45 | 9.47% | ― | 122.30% | 75.74% |
* General Sector Average
TSE:RX
Biosyent
14.00
2.49
21.61%
TSE:AQS
Aequus Pharmaceuticals
0.01
0.00
0.00%
TSE:ATLE
Willow Biosciences Inc
0.19
>-0.01
-4.52%
TSE:MDP
Medexus Pharmaceuticals Inc
3.92
1.28
48.48%
TSE:HLS
HLS Therapeutics Inc
4.64
-0.07
-1.49%
TSE:CRDL
Cardiol Therapeutics
1.79
0.32
21.77%
Biosyent Corporate Events
Business Operations and Strategy
BioSyent to Showcase Growth Strategy at 2026 Bloom Burton Healthcare Investor Conference
Positive
Apr 15, 2026
BioSyent Inc. will present at the 2026 Bloom Burton Co. Healthcare Investor Conference in Toronto, where President and CEO René Goehrum is scheduled to provide an overview of the company’s business and corporate activities to investors...
Business Operations and StrategyProduct-Related Announcements
BioSyent’s FeraMAX Tops Canadian Iron Supplement Rankings for 11th Straight Year
Positive
Apr 1, 2026
BioSyent’s flagship iron supplement brand FeraMAX has been named Canada’s number-one recommended over-the-counter iron supplement for the 11th consecutive year in a national survey of pharmacists and physicians. The recognition, which ...
Business Operations and Strategy
BioSyent Grants Restricted Share Units to Key Personnel
Positive
Mar 24, 2026
BioSyent Inc. has granted 44,222 Restricted Share Units to selected directors, officers, management and employees under its Restricted Share Unit Plan. These awards, which will fully vest on the third anniversary of the grant date, are intended to...
Business Operations and StrategyStock BuybackDividendsFinancial DisclosuresM&A Transactions
BioSyent Delivers Double-Digit 2025 Growth and Expands with Oral Health Acquisition
Positive
Mar 19, 2026
BioSyent reported strong financial results for the fourth quarter and full year 2025, with total sales rising 10% in Q4 and 23% for the year to $43.1 million, driven by double-digit growth in its Canadian pharmaceutical portfolio and triple-digit ...
Business Operations and StrategyM&A TransactionsPrivate Placements and Financing
BioSyent Closes $25.5 Million Acquisition of Dental Specialist Oral Science
Positive
Mar 2, 2026
BioSyent Inc. has closed its previously announced acquisition of Oral Science Inc., a privately owned Canadian distributor of specialized dental hygiene and oral health products based in Brossard, Quebec. The $25.5 million deal, structured as an a...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.